Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (11668)	9/18/2018 11:55:27 AM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 12215

RE: VKTX Just finished CC (I like to sleep longer this days, :-)) While I am gratified that VK2809 did have positive primary and secondary, and most importantly NO safety (so far NO) issue at 10 mg/day dose (I care less for QOD regime, maybe they can introduce 5 mg/day dose???),....there is several points that make me MAD! IS THERE ANY BIO-COMPANY THAT CAN REPORT STRAIT FORWARD RESULTS??? First, when company switch the importance of the end-points (those are pHeHF subjects , not NASH) and exclude arm as trial progress without reporting,...I PISS ON THEM! Second, when company report numbers for secondary and no numbers for primary (15-40%LDLc reduction relative to placebo is only range, and not mean/median),...I PISS ON THEM! Third, when company is talking too-much about option to scale down dose,...THAN I ASK: "WHAT IS FUCKING WRONG WITH CURRENT DOSE/REGIMEN???" Looking forward to full data presentation. I was slow this morning, so full position on VKTX is still in place.